ESR1 and breast cancer: In particular, the triple-negative breast cancer (TNBC) subtype represents 10–12% [2–4] of all breast cancers and is defined by the lack of estrogen receptor (ER), progesterone receptor (PR) expression, and human epidermal growth factor receptor 2 ((HER2) amplification.